Morgan Stanley Replimune Group, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Replimune Group, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,047,627 shares of REPL stock, worth $14.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,047,627

Previous 1,689,803 38.0%

Holding current value

$14.8 Million

Previous $18.5 Million 31.5%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$10.54 - $14.93 $6.77 Million - $9.59 Million	-642,176 Reduced 38.0%	1,047,627 $12.7 Million
Q3 2024 Nov 14, 2024	SELL	$8.09 - $11.23 $370,934 - $514,906	-45,851 Reduced 2.64%	1,689,803 $18.5 Million
Q2 2024 Oct 17, 2024	SELL	$5.01 - $9.46 $4.6 Million - $8.69 Million	-918,380 Reduced 34.6%	1,735,654 $15.6 Million
Q2 2024 Aug 14, 2024	SELL	$5.01 - $9.46 $4.6 Million - $8.69 Million	-918,380 Reduced 34.6%	1,735,654 $15.6 Million
Q1 2024 Oct 17, 2024	BUY	$6.87 - $9.31 $6.31 Million - $8.55 Million	918,380 Added 52.91%	2,654,034 $21.7 Million
Q1 2024 Aug 16, 2024	SELL	$6.87 - $9.31 $12.3 Million - $16.7 Million	-1,793,194 Reduced 40.32%	2,654,034 $21.7 Million
Q1 2024 May 15, 2024	SELL	$6.87 - $9.31 $12.3 Million - $16.7 Million	-1,793,194 Reduced 40.32%	2,654,034 $21.7 Million
Q4 2023 Aug 16, 2024	BUY	$6.75 - $16.18 $18.3 Million - $43.9 Million	2,711,574 Added 156.23%	4,447,228 $37.5 Million
Q4 2023 Feb 13, 2024	BUY	$6.75 - $16.18 $26.9 Million - $64.4 Million	3,977,869 Added 847.51%	4,447,228 $37.5 Million
Q3 2023 Nov 15, 2023	SELL	$15.96 - $22.18 $2.94 Million - $4.09 Million	-184,206 Reduced 28.18%	469,359 $8.03 Million
Q2 2023 Aug 14, 2023	SELL	$15.65 - $24.1 $3.07 Million - $4.72 Million	-195,884 Reduced 23.06%	653,565 $15.2 Million
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $4.11 Million - $6.84 Million	235,293 Added 38.31%	849,449 $15 Million
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $952,357 - $1.56 Million	55,726 Added 9.98%	614,156 $16.7 Million
Q3 2022 Nov 14, 2022	SELL	$15.6 - $21.15 $739,268 - $1 Million	-47,389 Reduced 7.82%	558,430 $9.65 Million
Q2 2022 Oct 27, 2022	BUY	$13.32 - $19.98 $252,707 - $379,060	18,972 Added 3.23%	605,819 $10.6 Million
Q2 2022 Aug 15, 2022	BUY	$13.32 - $19.98 $252,707 - $379,060	18,972 Added 3.23%	605,819 $10.6 Million
Q1 2022 Oct 27, 2022	SELL	$15.24 - $29.75 $289,133 - $564,417	-18,972 Reduced 3.13%	586,847 $9.97 Million
Q1 2022 May 13, 2022	BUY	$15.24 - $29.75 $3.58 Million - $7 Million	235,226 Added 66.9%	586,847 $9.97 Million
Q4 2021 Feb 14, 2022	SELL	$25.43 - $34.25 $173,127 - $233,174	-6,808 Reduced 1.9%	351,621 $9.53 Million
Q3 2021 Nov 15, 2021	BUY	$28.98 - $39.54 $10.4 Million - $14.2 Million	358,429 New	358,429 $10.6 Million

Others Institutions Holding REPL

# of Institutions

158

Shares Held

76.1M

Call Options Held

40.6K

Put Options Held

53K

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $695M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account